巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Amgen

AMGN
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Amgen - 延遲價格・最後更新於 24/01 12:15
最高位
229.290
最低位
219.930
開市價
--
前收市價
227.570
成交量(千)
328.61
成交額(百萬)
541.10
買入
--
賣出
--
每手股數
--
市值(百萬)
127,286.83
市盈率
23.300
息率
3.11%
差價
--
52週高低
276.690 - 198.640
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Amgen
證券代碼
AMGN.US
所屬板塊
Drug Manufacturers - General
公司業務
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), and Lumakras (lung cancer). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
發行量
563265902
公司總部
One Amgen Center Drive
公司網址
https://www.amgen.com
公司電郵
investor.relations@amgen.com
公司電話
+1 805 447-1000

百濟神州擬於科創板發行1.15億股A股

張偉倫·
百濟神州擬於科創板發行1.15億股A股

關於

Amgen(AMGN.US)所屬的行業板塊為Drug Manufacturers - General。
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), and Lumakras (lung cancer). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
截至24/01 12:15:00,Amgen的股價跌-0.70,市值127,286.83百萬。Amgen的市盈率及息率分別為23.300及3.11%。
詳細公司背景可參考: https://www.amgen.com